Skip to main content

Advertisement

Fig. 1 | Molecular Cancer

Fig. 1

From: MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells

Fig. 1

Serum miR155 was significantly elevated in DLBCL and indicated lymphoma progression. a As detected by real-time quantitative PCR, serum miR155 was higher in DLBCL patients than in health volunteers both in the training cohort and validation cohort. The relative expression level of each patient was calculated based on the lowest expression value. b Patients with high miR155 expression had significantly shorter progression-free survival time than those with low miR155 expression both in the training cohort and validation cohort calculated by survival analysis using SPSS version 20.0 statistical software. c A significant correlation was observed between serum and tumor miR155 expression level. Correlation coefficient was determined by Pearson correlation coefficient analysis via GraphPad Prism 5 software. d Patients with high miR155 expression displayed decreased serum CD3+T cells and CD3+CD8+T cells, as compared to those with low miR155 expression by analysing the peripheral blood immune cells using flow cytometry. e As revealed by enzyme-linked immunosorbent assay, serum IFN-γ level was higher in low miR155 group than in high miR155 group. f Serum miR155 was higher in EBV-positive patients than EBV-negative patients. EBV positivity was confirmed through EBV DNA quantification assay. The relative expression level of each patient was calculated based on the lowest expression value

Back to article page